Claims
- 1. A pyridine derivative represented by the general formula (1): wherein R1 represents a halogen atom or a halogen-substituted lower alkyl group; R2 and R3 are the same or different and represent a hydrogen atom or a halogen atom; V represents a group: —C(═O)—NH—, a group: —NH—C(═O)—, a group: —NH—C(═O)—NH— or a group: —CH═CH—; A represents a group A1: (wherein R4 represents a hydrogen atom or a 2-lower alkyl-1,3-dioxolane group; R5 represents a hydrogen atom or a 2-lower alkyl-1,3-dioxolane group; and R6 represents a hydrogen atom, provided that one of R4 and R5 is a 2-lower alkyl-1,3-dioxolane group and the other of R4 and R5 is a hydrogen atom), a group A2: ((wherein R7 represents a hydrogen atom or a lower alkyl group; R8 may be the same or different and represents a hydrogen atom, a hydroxyl group, an oxo group, a lower alkanoyloxy group, an aroyloxy group, a lower alkoxy group, a group: (wherein k represents an integer of 1 to 3) or a group: ═N—OR10 (wherein R10 represents a hydrogen atom, a lower alkyl group or a lower alkanoyl group); p represents an integer of 1 to 2; {overscore (----)}represents a single bond or a double bond; Y represents a group: —(CH2)m—, a group: ═CH(CH2)m-1— or a group: —(CH2)m-1CH═; and m represents an integer of 1 to 3)) or a group A3: ((wherein R9 may be the same or different and represents a hydrogen atom, a hydroxyl group, an oxo group, a lower alkanoyloxy group, an aroyloxy group, a lower alkoxy group, a group: (wherein k represents an integer of 1 to 3) or a group; 1 represents an a hydrogen atom, a lower alkyl group or a lower alkanoyl group); q represents an integer of 1 to 2; {overscore (----)}represents a single bond or a double bond; Z represents a group: —(CH2)n—, a group: ═CH(CH2)n-1— or a group: —(CH2)n-1CH═; and n represents an integer of 1 to 3)) or a salt thereof.
- 2. The pyridine derivative according to claim 1, wherein A is the group A2 or A3, or a salt thereof.
- 3. The pyridine derivative according to claim 2, wherein m and n are 1 or 2, or a salt thereof.
- 4. The pyridine derivative according to claim 3, wherein R8 and R9 are an oxo group or a lower alkanoyloxy group, or a salt thereof.
- 5. The pyridine derivative according to claim 1, wherein V is the group: —C(═O)—NH—, the group: —NH—C(═O)— or the group: —NH—C(═O)—NH—, or a salt thereof.
- 6. The pyridine derivative according to claim 5, wherein A is the group A2 or A3, or a salt thereof.
- 7. The pyridine derivative according to claim 1, wherein R1 and R2 are respectively a halogen atom, or a salt thereof.
- 8. The pyridine derivative according to claim 1, wherein R1 is a halogen-substituted lower alkyl group, or a salt thereof.
- 9. The pyridine derivative according to claim 6, wherein R1 and R2 are respectively a halogen atom, or a salt thereof.
- 10. The pyridine derivative according to claim 6, wherein R1 is a halogen-substituted alkyl group, or a salt thereof.
- 11. The pyridine derivative according to claim 7, wherein A is the group A2, or a salt thereof.
- 12. The pyridine derivative according to claim 11, wherein V is the group: —C(═O)—NH—, or a salt thereof.
- 13. The pyridine derivative according to claim 11, wherein V is the group: —NH—C(═O)—NH—, or a salt thereof.
- 14. The pyridine derivative according to claim 7, wherein A is the group A3, or a salt thereof.
- 15. The pyridine derivative according to claim 14, wherein V is the group: —NH—C(═O)—NH—, or a salt thereof.
- 16. The pyridine derivative according to claim 8, wherein A is the group A2, or a salt thereof.
- 17. The pyridine derivative according to claim 8, wherein A is the group A3, or a salt thereof.
- 18. The pyridine derivative according to claim 16, wherein V is the group: —NH—C(═O)—, or a salt thereof.
- 19. The pyridine derivative according to claim 16, wherein V is the group: —NH—C(═O)—NH—, or a salt thereof.
- 20. The pyridine derivative according to claim 17, wherein V is the group: —NH—C(═O)—NH—, or a salt thereof.
- 21. The pyridine derivative according to claim 12, wherein Y is a group: —CH═ or —CH2═, R7 is a hydrogen atom, R8 is an oxo group, a lower alkanoyloxy group or the group: —O—CH2—CH2—O—, or a salt thereof.
- 22. The pyridine derivative according to claim 13, wherein Y is the group: —CH═, —CH2—CH2— or —CH2—CH═, R7 is a hydrogen atom, R8 is an oxo group or a lower alkanoyloxy group, or a salt thereof.
- 23. The pyridine derivative according to claim 15, wherein Z is a group: —CH2—CH═, R9 is a lower alkanoyloxy group, or a salt thereof.
- 24. The pyridine derivative according to claim 18, wherein Y is the group: —CH2—, R7 is a hydrogen atom, R8 is an oxo group, or a salt thereof.
- 25. The pyridine derivative according to claim 19, wherein Y is the group: —CH2—, —CH═ or —CH2—CH═, R7 is a hydrogen atom, R8 is a lower alkanoyloxy group, or a salt thereof.
- 26. The pyridine derivative according to claim 20, wherein Z is the group,: —CH2—CH═, R9 is a lower alkanoyloxy group, or a salt thereof.
- 27. A pharmaceutical composition for prophylaxis or treatment of fibrosis, which comprises an effective amount of a compound of the general formula (1) wherein R1 represents a halogen atom or a halogen-substituted lower alkyl group; R2 and R3 are the same or different and represent a hydrogen atom or a halogen atom; V represents a group: —C(═O)—NH—, a group: —NH—C(═O)—, a group: —NH—C(═O)—NH— or a gruo: —CH═CH—; A represents a group A1: (wherein R4 represents a hydrogen atom or a 2-lower alkyl-1,3-dioxolane group; R5 represents a hydrogen atom or a 2-lower alkyl-1,3-dioxolane group; and R6 represents a hydrogen atom, provided that one of R4 and R5 is a 2-lower alkyl-1,3-dioxolane group and the other of R4 and R5 is a hydrogen atom), a group A2: ((wherein R7 represents a hydrogen atom or a lower alkyl group; R8 may be the same or different and represents a hydrogen atom, a hydroxyl group, an oxo group, a lower alkanoyloxy group, an aroyloxy group, a lower alkoxy group, a group: (wherein k represents an integer of 1 to 3) or a group: ═N—OR10 (wherein R10 represents a hydrogen atom, a lower alkyl group or a lower alkanoyl group); p represents an integer of 1 to 2; {overscore (----)}represents a single bond or a double bond; Y represents a group: —(CH2)m—, a group: ═CH(CH2)m-1— or a group: —(CH2)m-1CH═; and m represents an integer of 1 to 3)) or a group A3: ((wherein R9 may be the same or different and represents a hydrogen atom, a hydroxyl group, an oxo group, a lower alkanoyloxy group, an aroyloxy group, a lower alkoxy group, a group: (wherein k represents an integer of 1 to 3) or a group: ═N—OR10 (wherein R10 represents a hydrogen atom, a lower alkyl group or a lower alkanoyl group); q represents an integer of 1 to 2; {overscore (----)}isclosure of the Inventionrepresents a single bond or a double bond; Z represents a group: —(CH2)n—, a group: ═CH(CH2)n-1— or a group: —(CH2)n-1CH═; and n represents an integer of 1 to 3)) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent and/or excipient.
- 28. A method for inhibiting fibrogenesis caused by excess production of collagen in a mammal which comprises administering to said mammal a pharmaceutically effective amount of a compound of the general formula (1) wherein R1 represents a halogen atom or a halogen-substituted lower alkyl group; R2 and R3 are the same or different and represent a hydrogen atom or a halogen atom; V represents a group: —C(═O)—NH—, a group: —NH—C(═O)—, a group: —NH—C(═O)—NH— or a group: —CH═CH—; A represents a group A1: (wherein R4 represents a hydrogen atom, a 2-lower alkyl-1,3-dioxolane group or a hydroxy-substituted lower alkyl group; R5 represents a hydrogen atom, or a 2-lower alkyl-1,3-dioxolane group; and R6 represents a hydrogen atom, provided that R4 and R5 do not both represent a hydrogen atom at the same time), a group A2: ((wherein R7 represents a hydrogen atom or a lower alkyl group; R8 may be the same or different and represents a hydrogen atom, a hydroxyl group, an oxo group, a lower alkanoyloxy group, an aroyloxy group, a lower alkoxy group, a group: (wherein k represents an integer of 1 to 3) or a group: ═N—OR10 (wherein R10 represents a hydrogen atom, a lower alkyl group or a lower alkanoyl group); p represents an integer of 1 to 2; {overscore (----)}represents a single bond or a double bond; Y represents a group: —(CH2)m—, a group: ═CH(CH2)m-1— or a group: —(CH2)m-1CH—; and m represents an integer of 1 to 3)) or a group A3: ((wherein R9 may be the same or different and represents a hydrogen atom, a hydroxyl group, an oxo group, a lower alkanoyloxy group, an aroyloxy group, a lower alkoxy group, a group: (wherein k represents an integer of 1 to 3) or a group: ═N—OR10 (wherein R10 represents a hydrogen atom, a lower alkyl group or a lower alkanoyl group); q represents an integer of 1 to 2; {overscore (----)}represents a single bond or a double bond; Z represents a group: —(CH2)n—, a group: ═CH(CH2)n-1— or a group: —(CH2)n-1CH═; and n represents an integer of 1 to 3)) or a pharmaceutically salt thereof.
Priority Claims (2)
Number |
Date |
Country |
Kind |
10-078083 |
Mar 1998 |
JP |
|
10-251552 |
Sep 1998 |
JP |
|
Parent Case Info
This application is a 371 of PCT/JP99/01425, Mar. 19, 1999 now WO 99/48,871.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/JP99/01425 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO99/48871 |
9/30/1999 |
WO |
A |
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
6022884 |
Mantlo et al. |
Feb 2000 |
A |
Foreign Referenced Citations (2)
Number |
Date |
Country |
0 562 512 |
Sep 1993 |
EP |
WO 9924404 |
May 1999 |
WO |